Published in Mol Pharm on January 12, 2004
Interpretation of antibiotic concentration ratios measured in epithelial lining fluid. Antimicrob Agents Chemother (2007) 2.05
Preparation and in vivo evaluation of SMEDDS (self-microemulsifying drug delivery system) containing fenofibrate. AAPS J (2007) 1.59
The use of BDDCS in classifying the permeability of marketed drugs. Pharm Res (2008) 1.57
The role of transporters in the pharmacokinetics of orally administered drugs. Pharm Res (2009) 1.46
Prediction of solubility and permeability class membership: provisional BCS classification of the world's top oral drugs. AAPS J (2009) 1.37
Advanced drug delivery systems of curcumin for cancer chemoprevention. Cancer Prev Res (Phila) (2011) 1.17
Synthetic EthR inhibitors boost antituberculous activity of ethionamide. Nat Med (2009) 1.16
Physicochemical characterization of efavirenz-cyclodextrin inclusion complexes. AAPS PharmSciTech (2009) 1.09
Application of gastrointestinal simulation for extensions for biowaivers of highly permeable compounds. AAPS J (2008) 1.05
Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability. J Int AIDS Soc (2013) 1.05
A cell-based molecular transport simulator for pharmacokinetic prediction and cheminformatic exploration. Mol Pharm (2006) 1.03
Bioequivalence of orally administered generic, compounded, and innovator-formulated itraconazole in healthy dogs. J Vet Intern Med (2013) 1.02
Understanding the effect of API properties on bioavailability through absorption modeling. AAPS J (2008) 1.02
Prediction of modified release pharmacokinetics and pharmacodynamics from in vitro, immediate release, and intravenous data. AAPS J (2009) 1.01
How drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusion. Front Pharmacol (2014) 1.00
Solid state characterization of commercial crystalline and amorphous atorvastatin calcium samples. AAPS PharmSciTech (2010) 0.98
In vitro plasma stability, permeability and solubility of mercaptoacetamide histone deacetylase inhibitors. Int J Pharm (2008) 0.96
The Biopharmaceutics Classification System: subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC. Eur J Pharm Sci (2014) 0.95
Enabling the intestinal absorption of highly polar antiviral agents: ion-pair facilitated membrane permeation of zanamivir heptyl ester and guanidino oseltamivir. Mol Pharm (2010) 0.93
Nanotechnology-applied curcumin for different diseases therapy. Biomed Res Int (2014) 0.90
Controlled release matrix tablets of olanzapine: influence of polymers on the in vitro release and bioavailability. AAPS PharmSciTech (2010) 0.89
Preparation and evaluation of self-nanoemulsifying tablets of carvedilol. AAPS PharmSciTech (2009) 0.88
An uncharged oxetanyl sulfoxide as a covalent modifier for improving aqueous solubility. ACS Med Chem Lett (2014) 0.87
Physiologically Based Pharmacokinetic Modeling of Tamoxifen and its Metabolites in Women of Different CYP2D6 Phenotypes Provides New Insight into the Tamoxifen Mass Balance. Front Pharmacol (2012) 0.87
Trends in oral drug bioavailability following bariatric surgery: examining the variable extent of impact on exposure of different drug classes. Br J Clin Pharmacol (2012) 0.86
Development of lipid-based nanoparticles for enhancing the oral bioavailability of paclitaxel. AAPS PharmSciTech (2011) 0.86
Luciferase-Based, High-Throughput Assay for Screening and Profiling Transmission-Blocking Compounds against Plasmodium falciparum Gametocytes. Antimicrob Agents Chemother (2016) 0.85
A standardized mini paddle apparatus as an alternative to the standard paddle. AAPS PharmSciTech (2008) 0.85
Preclinical monitoring of drug association in experimental chemotherapy of Chagas' disease by a new HPLC-UV method. Antimicrob Agents Chemother (2012) 0.84
The H2 receptor antagonist nizatidine is a P-glycoprotein substrate: characterization of its intestinal epithelial cell efflux transport. AAPS J (2009) 0.83
Preparation and characterization of solid dispersions of carvedilol with PVP K30. Res Pharm Sci (2010) 0.83
In silico prediction of drug dissolution and absorption with variation in intestinal pH for BCS class II weak acid drugs: ibuprofen and ketoprofen. Biopharm Drug Dispos (2012) 0.82
Physico-mechanical and stability evaluation of carbamazepine cocrystal with nicotinamide. AAPS PharmSciTech (2011) 0.82
Practical anticipation of human efficacious doses and pharmacokinetics using in vitro and preclinical in vivo data. AAPS J (2009) 0.81
Solubility enhancement of simvastatin by arginine: thermodynamics, solute-solvent interactions, and spectral analysis. Drug Des Devel Ther (2016) 0.81
Simulations of the nonlinear dose dependence for substrates of influx and efflux transporters in the human intestine. AAPS J (2009) 0.81
In vitro enhancement of lactate esters on the percutaneous penetration of drugs with different lipophilicity. AAPS PharmSciTech (2010) 0.80
Pharmacogenomics of Methotrexate Membrane Transport Pathway: Can Clinical Response to Methotrexate in Rheumatoid Arthritis Be Predicted? Int J Mol Sci (2015) 0.80
The utility of self-emulsifying oil formulation to improve the poor solubility of the anti HIV drug CSIC. AIDS Res Ther (2013) 0.80
Structure-activity studies of Wnt/β-catenin inhibition in the Niclosamide chemotype: Identification of derivatives with improved drug exposure. Bioorg Med Chem (2015) 0.80
In vitro-in vivo correlation of efavirenz tablets using GastroPlus®. AAPS PharmSciTech (2013) 0.79
Native aggregation as a cause of origin of temporary cellular structures needed for all forms of cellular activity, signaling and transformations. Theor Biol Med Model (2010) 0.79
Provisional in-silico biopharmaceutics classification (BCS) to guide oral drug product development. Drug Des Devel Ther (2014) 0.78
Evaluation of the membrane permeability (PAMPA and skin) of benzimidazoles with potential cannabinoid activity and their relation with the Biopharmaceutics Classification System (BCS). AAPS PharmSciTech (2011) 0.78
PharmGKB summary: isoniazid pathway, pharmacokinetics. Pharmacogenet Genomics (2016) 0.77
Applying Biopharmaceutical Classification System (BCS) Criteria to Predict Oral Absorption of Drugs in Dogs: Challenges and Pitfalls. AAPS J (2015) 0.77
Design and in vivo evaluation of oxycodone once-a-day controlled-release tablets. Drug Des Devel Ther (2015) 0.77
Floating elementary osmotic pump tablet (FEOPT) for controlled delivery of diethylcarbamazine citrate: a water-soluble drug. AAPS PharmSciTech (2011) 0.77
Effect of clarithromycin and fluconazole on the pharmacokinetics of montelukast in human volunteers. Eur J Clin Pharmacol (2012) 0.77
Development and validation of a discriminative dissolution method for atorvastatin calcium tablets using in vivo data by LC and UV methods. AAPS PharmSciTech (2013) 0.77
Formulation and in vitro evaluation of rifampicin loaded porous microspheres. Sci Pharm (2010) 0.76
Chitosan based atorvastatin nanocrystals: effect of cationic charge on particle size, formulation stability, and in-vivo efficacy. Int J Nanomedicine (2015) 0.76
Effect of cyclodextrin complexation on the aqueous solubility and solubility/dose ratio of praziquantel. AAPS PharmSciTech (2009) 0.76
Antiretroviral Drugs-Loaded Nanoparticles Fabricated by Dispersion Polymerization with Potential for HIV/AIDS Treatment. Infect Dis (Auckl) (2016) 0.75
Tween-embedded microemulsions--physicochemical and spectroscopic analysis for antitubercular drugs. AAPS PharmSciTech (2010) 0.75
TSPO Ligand-Methotrexate Prodrug Conjugates: Design, Synthesis, and Biological Evaluation. Int J Mol Sci (2016) 0.75
Regulating drug release behavior and kinetics from matrix tablets based on fine particle-sized ethyl cellulose ether derivatives: an in vitro and in vivo evaluation. ScientificWorldJournal (2012) 0.75
Pediatric Biopharmaceutical Classification System: Using Age-Appropriate Initial Gastric Volume. AAPS J (2016) 0.75
Pain management in trauma: A review study. J Inj Violence Res (2016) 0.75
Tyloxapol niosomes as prospective drug delivery module for antiretroviral drug nevirapine. AAPS PharmSciTech (2014) 0.75
Factors to consider in developing individual pharmaceutical product quality risk profiles useful to government procurement agencies. Acta Pharm Sin B (2015) 0.75
Evaluation of the intestinal permeability of rosemary (Rosmarinus officinalis L.) extract polyphenols and terpenoids in Caco-2 cell monolayers. PLoS One (2017) 0.75
Solvated crystalline forms of nevirapine: thermoanalytical and spectroscopic studies. AAPS PharmSciTech (2010) 0.75
A case study of in silico modelling of ciprofloxacin hydrochloride/metallic compound interactions. AAPS PharmSciTech (2013) 0.75
Drug resinates an attractive approach of solubility enhancement of atorvastatin calcium. Indian J Pharm Sci (2013) 0.75
Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. Pharm Res (2007) 7.87
A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan. Mol Pharm (2006) 2.07
FIP/AAPS guidelines to dissolution/in vitro release testing of novel/special dosage forms. AAPS PharmSciTech (2003) 2.03
A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals. J Clin Pharmacol (2002) 1.85
Assuring quality and performance of sustained and controlled release parenterals: workshop report. AAPS PharmSci (2002) 1.84
Biopharmaceutics classification system: the scientific basis for biowaiver extensions. Pharm Res (2002) 1.74
Polymer degradation and in vitro release of a model protein from poly(D,L-lactide-co-glycolide) nano- and microparticles. J Control Release (2003) 1.72
Stability profiles of drug products extended beyond labeled expiration dates. J Pharm Sci (2006) 1.64
Applications of process analytical technology to crystallization processes. Adv Drug Deliv Rev (2004) 1.60
The use of BDDCS in classifying the permeability of marketed drugs. Pharm Res (2008) 1.57
Gastrointestinal metabolism of a vegetable-oil emulsion in healthy subjects. Am J Clin Nutr (2010) 1.51
Lessons learned from marketed and investigational prodrugs. J Med Chem (2004) 1.43
Summary workshop report: biopharmaceutics classification system--implementation challenges and extension opportunities. J Pharm Sci (2004) 1.43
Non-invasive pulmonary aerosol delivery in mice by the endotracheal route. Eur J Pharm Biopharm (2005) 1.39
[Proposals on the innovation policy by Ostros--correct diagnosis but wrong treatment]. Lakartidningen (2004) 1.39
Comparison of human duodenum and Caco-2 gene expression profiles for 12,000 gene sequences tags and correlation with permeability of 26 drugs. Pharm Res (2002) 1.37
Prediction of solubility and permeability class membership: provisional BCS classification of the world's top oral drugs. AAPS J (2009) 1.37
Transfection efficiency and toxicity of polyethylenimine in differentiated Calu-3 and nondifferentiated COS-1 cell cultures. AAPS PharmSci (2002) 1.36
AAPS-FDA workshop white paper: microdialysis principles, application and regulatory perspectives. Pharm Res (2007) 1.35
Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets. Clin Neuropharmacol (2003) 1.33
Bioequivalence; its history, practice, and future. AAPS J (2009) 1.30
Chitosan microparticles for mucosal vaccination against diphtheria: oral and nasal efficacy studies in mice. Vaccine (2003) 1.29
Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. Pharm Res (2006) 1.26
PLGA-PEI nanoparticles for gene delivery to pulmonary epithelium. Eur J Pharm Biopharm (2004) 1.23
Transdermal drug delivery system (TDDS) adhesion as a critical safety, efficacy and quality attribute. Eur J Pharm Biopharm (2006) 1.22
Amino acid ester prodrugs of the anticancer agent gemcitabine: synthesis, bioconversion, metabolic bioevasion, and hPEPT1-mediated transport. Mol Pharm (2005) 1.21
Identification of a human valacyclovirase: biphenyl hydrolase-like protein as valacyclovir hydrolase. J Biol Chem (2003) 1.19
Physiological parameters for oral delivery and in vitro testing. Mol Pharm (2010) 1.18
The suitability of an in situ perfusion model for permeability determinations: utility for BCS class I biowaiver requests. Mol Pharm (2006) 1.16
Preparation and characterization of protein-loaded N-trimethyl chitosan nanoparticles as nasal delivery system. J Control Release (2005) 1.13
Toward global standards for comparator pharmaceutical products: case studies of amoxicillin, metronidazole, and zidovudine in the Americas. AAPS J (2012) 1.12
The BCS, BDDCS, and regulatory guidances. Pharm Res (2011) 1.11
Bias in estimation of transporter kinetic parameters from overexpression systems: Interplay of transporter expression level and substrate affinity. J Pharmacol Exp Ther (2006) 1.10
Pharmacokinetics of an immediate release, a controlled release and a two pulse dosage form in dogs. Eur J Pharm Biopharm (2005) 1.10
Effect of interleukin-1beta and tumor necrosis factor-alpha on gene expression in human endothelial cells. Am J Physiol Cell Physiol (2003) 1.09
Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol (2009) 1.08
In vitro and in vivo evaluation of a new sublingual tablet system for rapid oromucosal absorption using fentanyl citrate as the active substance. Eur J Pharm Sci (2003) 1.08
Quantitative determination of cesium binding to ferric hexacyanoferrate: Prussian blue. J Pharm Biomed Anal (2007) 1.07
Generic products of antiepileptic drugs: a perspective on bioequivalence and interchangeability. Epilepsia (2010) 1.07
The effects of food on the dissolution of poorly soluble drugs in human and in model small intestinal fluids. Pharm Res (2005) 1.07
In vitro evaluation of intestinal absorption of desmopressin using drug-delivery systems based on superporous hydrogels. Int J Pharm (2004) 1.07
Drug transport and metabolism characteristics of the human airway epithelial cell line Calu-3. J Control Release (2003) 1.05
Uptake studies in rat Peyer's patches, cytotoxicity and release studies of alginate coated chitosan nanoparticles for mucosal vaccination. J Control Release (2006) 1.04
A novel nucleoside prodrug-activating enzyme: substrate specificity of biphenyl hydrolase-like protein. Mol Pharm (2005) 1.04
Quality-by-design (QbD): effects of testing parameters and formulation variables on the segregation tendency of pharmaceutical powder measured by the ASTM D 6940-04 segregation tester. J Pharm Sci (2008) 1.04
Molecular basis of prodrug activation by human valacyclovirase, an alpha-amino acid ester hydrolase. J Biol Chem (2008) 1.04
Floxuridine amino acid ester prodrugs: enhancing Caco-2 permeability and resistance to glycosidic bond metabolism. Pharm Res (2005) 1.04
Targeted delivery to PEPT1-overexpressing cells: acidic, basic, and secondary floxuridine amino acid ester prodrugs. Mol Cancer Ther (2005) 1.03
Summary workshop report: bioequivalence, biopharmaceutics classification system, and beyond. AAPS J (2008) 1.01
Gene and protein expression of P-glycoprotein, MRP1, MRP2, and CYP3A4 in the small and large human intestine. Mol Pharm (2007) 1.01
AAPS-FDA Workshop White Paper: microdialysis principles, application, and regulatory perspectives. J Clin Pharmacol (2007) 1.01
Levodopa pharmacokinetics and motor performance during activities of daily living in patients with Parkinson's disease on individual drug combinations. Clin Neuropharmacol (2002) 1.00
Multiple efflux pumps are involved in the transepithelial transport of colchicine: combined effect of p-glycoprotein and multidrug resistance-associated protein 2 leads to decreased intestinal absorption throughout the entire small intestine. Drug Metab Dispos (2009) 1.00
Amino acid ester prodrugs of floxuridine: synthesis and effects of structure, stereochemistry, and site of esterification on the rate of hydrolysis. Pharm Res (2003) 1.00
Gene expression in the human intestine and correlation with oral valacyclovir pharmacokinetic parameters. J Pharmacol Exp Ther (2003) 0.99
Transport characteristics of fexofenadine in the Caco-2 cell model. Pharm Res (2004) 0.99
Assuring quality and performance of sustained and controlled release parenterals: AAPS workshop report, co-sponsored by FDA and USP. Pharm Res (2002) 0.99
High-permeability criterion for BCS classification: segmental/pH dependent permeability considerations. Mol Pharm (2010) 0.99
Segmental dependent transport of low permeability compounds along the small intestine due to P-glycoprotein: the role of efflux transport in the oral absorption of BCS class III drugs. Mol Pharm (2009) 0.98
Comparative gene expression profiles of intestinal transporters in mice, rats and humans. Pharmacol Res (2007) 0.98
Assessment of dermatopharmacokinetic approach in the bioequivalence determination of topical tretinoin gel products. J Am Acad Dermatol (2003) 0.98
Evaluation of USP apparatus 3 for dissolution testing of immediate-release products. AAPS PharmSci (2002) 0.98
In vitro testing of drug absorption for drug 'developability' assessment: forming an interface between in vitro preclinical data and clinical outcome. Curr Opin Drug Discov Devel (2004) 0.97
Enhancing the intestinal membrane permeability of zanamivir: a carrier mediated prodrug approach. Mol Pharm (2011) 0.96
Adrenal insufficiency: review of clinical outcomes with current glucocorticoid replacement therapy. Clin Endocrinol (Oxf) (2014) 0.96
Mucosal vaccines: recent progress in understanding the natural barriers. Pharm Res (2009) 0.95
Toward an increased understanding of the barriers to colonic drug absorption in humans: implications for early controlled release candidate assessment. Mol Pharm (2009) 0.95
Conference report: Bio-International 2005. J Pharm Sci (2007) 0.95
Scientific considerations of pharmaceutical solid polymorphism in abbreviated new drug applications. Pharm Res (2003) 0.95
Blockade of interleukin-6 receptor suppresses the proliferation of H460 lung cancer stem cells. Int J Oncol (2012) 0.95
The solubility-permeability interplay in using cyclodextrins as pharmaceutical solubilizers: mechanistic modeling and application to progesterone. J Pharm Sci (2010) 0.95
Feasibility of biowaiver extension to biopharmaceutics classification system class III drug products: cimetidine. Clin Pharmacokinet (2006) 0.95
A topological substructural approach for the prediction of P-glycoprotein substrates. J Pharm Sci (2006) 0.95
N-trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination: biological properties and immunogenicity in a mouse model. Vaccine (2006) 0.94
Induction of lymphocytes activated marker CD69 following exposure to chitosan and alginate biopolymers. Int J Pharm (2007) 0.94
Grapefruit juice and its constituents augment colchicine intestinal absorption: potential hazardous interaction and the role of p-glycoprotein. Pharm Res (2008) 0.94
Surfactant-mediated dissolution: contributions of solubility enhancement and relatively low micelle diffusivity. J Pharm Sci (2004) 0.94
Pulmonary absorption rate and bioavailability of drugs in vivo in rats: structure-absorption relationships and physicochemical profiling of inhaled drugs. J Pharm Sci (2003) 0.93
Methylphenidate blood levels and therapeutic response in children with attention-deficit hyperactivity disorder: I. Effects of different dosing regimens. J Child Adolesc Psychopharmacol (2006) 0.93
Enhanced cancer cell growth inhibition by dipeptide prodrugs of floxuridine: increased transporter affinity and metabolic stability. Mol Pharm (2008) 0.93
Tacrolimus is a class II low-solubility high-permeability drug: the effect of P-glycoprotein efflux on regional permeability of tacrolimus in rats. J Pharm Sci (2002) 0.93
Enabling the intestinal absorption of highly polar antiviral agents: ion-pair facilitated membrane permeation of zanamivir heptyl ester and guanidino oseltamivir. Mol Pharm (2010) 0.93
Irregular gastrointestinal drug absorption in Parkinson's disease. Expert Opin Drug Metab Toxicol (2008) 0.93
Peroral delivery systems based on superporous hydrogel polymers: release characteristics for the peptide drugs buserelin, octreotide and insulin. Eur J Pharm Sci (2002) 0.92
Stability of valacyclovir: implications for its oral bioavailability. Int J Pharm (2006) 0.92
Increasing oral absorption of polar neuraminidase inhibitors: a prodrug transporter approach applied to oseltamivir analogue. Mol Pharm (2013) 0.92